Letterlife is a technology company.
Letterlife has raised $750K across 1 funding round.
Letterlife has raised $750K in total across 1 funding round.
Letterlife has raised $750K in total across 1 funding round.
Letterlife's investors include Icebreaker.vc.
Letterlife is a Swedish digital health company building an app and complementary services for women with ADHD, providing a community, expert access, coaching, and personalized tools to manage symptoms, medication, and lifestyle. It serves neurodiverse women seeking support beyond traditional healthcare, solving gaps in ADHD care like diagnostic delays, gender-specific needs, and limited access to evidence-based strategies amid rising ADHD awareness.[1][2][4]
The platform offers a self-serve app for peer matching, expert Q&A from doctors and therapists, and knowledge hubs; premium coaching and daily support address daily challenges, menstrual cycle interactions with medication, and building routines. Founded on research, it emphasizes holistic, science-backed approaches, with strong early momentum from clinician collaborations and patient-led development.[1][2][4]
Letterlife emerged from one of Sweden's first research studies on women with ADHD, evolving into a digital tool through collaboration among patients, clinicians, and developers. Associate Professor Lotta Borg Skoglund, a psychiatrist, author of *ADHD Girls to Women* (2023), and founder of Smart Psykiatri clinic, leads the effort alongside experts like Associate Professor Helena Kopp Kallner (gynecology, Karolinska Institutet) and Professor Lisa Thorell (developmental psychology).[1][2][5]
The idea stemmed from unmet needs in healthcare—insufficient support for female ADHD symptoms, hormone fluctuations, and comorbidities—spurred by patient voices and studies like the GODDESS ADHD project. Pivotal early traction came from qualitative research, user co-design, and integration of active/passive monitoring for real-life data, launching as Letterlife AB (reg. 559940-3800) in Stockholm.[2][3][5]
Letterlife rides the neurodiversity and women's digital health wave, targeting underdiagnosed female ADHD amid growing awareness of gender biases in psychiatry. Timing aligns with post-pandemic mental health surges, precision medicine advances, and femtech boom (e.g., cycle-tracking apps), where market forces like rising ADHD diagnoses in women and demand for non-pharma tools favor scalable apps.[1][2][5]
It influences the ecosystem by bridging research-clinical gaps via patient co-creation, contributing to outcomes like reduced polypharmacy and better reproductive health—potentially lowering societal costs. As femtech grows, Letterlife exemplifies evidence-driven, inclusive platforms amplifying clinician-patient networks.[2][5]
Letterlife is poised for expansion by leveraging its research pipeline (e.g., GODDESS validations) into international markets, AI-enhanced personalization, and partnerships with pharma/health systems. Trends like AI monitoring, global ADHD awareness, and holistic femtech will propel growth, evolving its role from niche app to precision health leader for neurodiverse women—ultimately redefining ADHD support from reactive to proactive.[2][5]
Letterlife has raised $750K across 1 funding round. Most recently, it raised $750K Seed in September 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2023 | $750K Seed | Icebreaker.vc |